MDG1 Stock Chart & Stats
$0.02
<$0.01(11.76%)
―
--
Day’s Range― - ―
52-Week Range$0.01 - $0.15
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
€293.29K
Enterprise Value-$3.76M
Total Cash (Recent Filing)€14.02M
Total Debt (Recent Filing)€2.54M
Price to Earnings (P/E)―
Beta1.80
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding14,887,594
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.84
Price to Sales (P/S)6.41
P/FCF Ratio-2.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Medigene News
MDG1 FAQ
What was Medigene AG’s price range in the past 12 months?
Medigene AG lowest stock price was $0.01 and its highest was $0.15 in the past 12 months.
What is Medigene AG’s market cap?
Medigene AG’s market cap is €293.29K.
When is Medigene AG’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Medigene AG’s earnings last quarter?
Currently, no data Available
Is Medigene AG overvalued?
According to Wall Street analysts Medigene AG’s price is currently Undervalued.
Does Medigene AG pay dividends?
Medigene AG does not currently pay dividends.
What is Medigene AG’s EPS estimate?
Medigene AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medigene AG have?
Medigene AG has 14,887,594 shares outstanding.
What happened to Medigene AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Medigene AG?
Currently, no hedge funds are holding shares in DE:MDG1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medigene AG
Medigene AG is presently engaged in the liquidation of its residual assets. Its prior endeavors centered on advancing T-cell therapies designed to combat cancer. The company was founded in 1994 and maintains its principal office in Munich, Germany.